Vaginal energy-based devices: characterization of adverse events based on the last decade of MAUDE safety reports
- 28 September 2020
- journal article
- conference paper
- Published by Wolters Kluwer Health in Menopause
- Vol. 28 (2) , 135-141
Abstract
Objectives: Energy-based devices have gained momentum as minimally invasive procedures to treat both medical and cosmetic pelvic floor disorders including genitourinary syndrome of menopause, vaginal laxity, stress urinary incontinence, dyspareunia, and vulvar disorders such as lichen diseases and vestibulitis. However, the FDA recently issued a statement cautioning patients and providers that the safety and efficacy of energy-based devices for the treatment of vaginal symptoms has not been well established. Additionally, the FDA sent letters to the manufactures of energy-based devices with notifications that they could be violating the marketing standards of the FDA. The existing data on side effects is insufficient and limited to observational studies. We sought to characterize the safety events of vaginal energy-based devices by analysis of surveillance data from the FDA Manufacturer and User Facility Device Experience (MAUDE) database and specifically look at those events that occurred prior to the July 30, 2018 warning. Methods: The MAUDE database was queried between September 30, 2013 and October 31, 2019 for all vaginal energy-based devices. The incidence of safety events was reported for these devices and the most common complaints were described and characterized. Event reporting was analyzed before and after July 30, 2018. Results: Forty-two unique and relevant medical device reports (MDRs) were retrieved. The Mona Lisa Touch had the highest number of MDRs (40.5%) followed by ThermiVa (16.7%) and Viveve (14.2%). Each medical device report was associated with a single patient experience and within the 42 medical device reports, there were 85 complaints. A majority of the MDR complaints (52.9%) were also indications for energy-based devices procedures, which include vaginal pain, dyspareunia, lichen sclerosis, and urinary frequency. Two-thirds of the complaints (68.2%) were related to pain, but serious adverse events such as third-degree burns (3.5%) were rare. Most of the reportable events occurred before July 30, 2018 (83.3%), but most were reported after July 30, 2018 (78.6%). Conclusions: MAUDE-reported data suggests that the majority of patient complaints after vaginal energy-based device treatment include vaginal pain, bladder pain, and urinary symptoms. This study suggests that the majority of complaints are not severe, and some may be related to progression of the disease. The few severe adverse events reported in the MAUDE database may have contributed to the FDA warning regarding energy-based devices. Recall bias after the FDA warning, as well as the potential for litigation, may have prompted an increase in adverse event reporting after July 30, 2018. Video Summary: http://links.lww.com/MENO/A650.Keywords
This publication has 26 references indexed in Scilit:
- Use of a novel fractional CO2 laser for the treatment of genitourinary syndrome of menopause: 1-year outcomesMenopause, 2017
- Light and energy based therapeutics for genitourinary syndrome of menopause: Consensus and controversiesLasers in Surgery and Medicine, 2017
- Non-ablative erbium YAG laser for the treatment of type III stress urinary incontinence (intrinsic sphincter deficiency)Lasers in Medical Science, 2017
- Effect of Single-Treatment, Surface-Cooled Radiofrequency Therapy on Vaginal Laxity and Female Sexual Function: The VIVEVE I Randomized Controlled TrialThe Journal of Sexual Medicine, 2017
- An assessment of the safety and efficacy of a fractional CO2 laser system for the treatment of vulvovaginal atrophyMenopause, 2016
- Efficacy of Erbium:YAG laser treatment compared to topical estriol treatment for symptoms of genitourinary syndrome of menopauseLasers in Surgery and Medicine, 2016
- Histological study on the effects of microablative fractional CO2 laser on atrophic vaginal tissueMenopause, 2015
- Sexual function after fractional microablative CO2laser in women with vulvovaginal atrophyClimacteric, 2014
- Vaginal estrogen use in postmenopausal women with pelvic floor disorders: systematic review and practice guidelinesInternational Urogynecology Journal, 2014
- A 12-week treatment with fractional CO2laser for vulvovaginal atrophy: a pilot studyClimacteric, 2014